• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

June 27, 2011 By Barry Friedman Leave a Comment

CDER NAMES THESE TEN (21 CFR 211)

Comment

The following represent those most frequent Observations that CDER posted for fiscal year 2010 based on a total of 646 FDA Form 483. 

REFERENCE              FREQUENCY                        SHORT DESCRIPTION

211.22(d)                      149                        Procedures not in writing, fully followed

211.100(b)                   104                        SOPs not followed/documented

211.192                          98                         Investigations of discrepancies, failures

211.160(b)                    83                         Scientifically sound laboratory controls

211.110(a)                     82                         Control procedures to monitor and                                                                                       validate performance

211.100(a)                     81                         Absence of written procedures

211.167(b)                   71                          Written procedures not established/                                                                                               followed

211.25(a)                     66                           Training-operations, GMPs, written                                                                                      procedures

211.67(a)                     61                           Cleaning/sanitizing/maintenance

211.68(a)                     60                           Calibration/inspection/checking not   done

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Filed Under: 483, FDA Compliance, Regulatory Compliance Tagged With: 21 CFR 211, CDER, FDA Form 483, Fiscal 2010, Observations, Top ten

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.